辐射防护药物研究最新进展  

Recent advances in radioprotective agents

作　　者：张源 杨福军[1] 徐文清[1] Zhang Yuan Yang Fujun Xu Wenqing(Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Science, Tianjin 300192, China)

机构地区：[1]中国医学科学院放射医学研究所天津市放射医学与分子核医学重点实验室,天津300192

出　　处：《国际放射医学核医学杂志》2017年第5期353-358,共6页International Journal of Radiation Medicine and Nuclear Medicine

基　　金：国家自然科学基金（81273005）;中国医学科学院放射医学研究所发展基金（SF1528）

摘　　要：电离辐射损伤不仅是一个公众健康问题，同时也是一个国家安全问题。如何获得治疗效果优良、安全性高和不良反应小的辐射防护药物一直是科学家努力研究的目标。近年来，伴随着分子生物学、免疫学等学科的发展，辐射防护药物的研究也取得了较大的突破。目前，诸如5-雄烯二醇（5-AED）、CBLB502、Ex—RAD和HemaMax等药物已获得美国食品药品监督管理局的批准进入临床试验；而新发现的具有潜在价值的LY294002和17-DMAG等药物也正处于研发之中。笔者基于近年来辐射防护领域国外相关刊物和专利的最新发现和进展进行综述。重点放在近几年来出现的药物新进展以及这一时间内治疗急性放射综合征的抗辐射新药上。Ionizing radiation damage is not only a public health problem but is also a national security issue. Excellent treatment effect, high safety, and small side effects of radioprotective agents have been the goal of scientists attempting to study this concern. In recent years, research on radioprotective agents, along with the development of molecular biology, immunology, and other disciplines, has reached an advanced breakthrough. At present, drugs such as 5-androstenediol （5-AED）, CBLB502, Ex-RAD, and HemaMax have been approved by the US Food and Drug Administration for clinical trials, and newly discovered drugs such as LY294002 and 17-DMAG are under development. This paper is based on the recent discoveries and progress of foreign-related publications and patents in the field of radiation protection. New advances in drugs, as well as anti-radiation drugs for acute radiation syndrome, have been the focus of recent studies.

关 键 词：辐射防护药 胃肠综合征 造血综合征 电离辐射 临床研究 

分 类 号：R98[医药卫生—药品]